Indo Us Biotech DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025


0.87×	0.94×	0.98×
0.65×	0.86×	0.93×
7.9%	14.6%	17.2%
0.96×	0.96×	1.06×
1.53×	1.44×	1.25×
6.6%	16.4%	20.7%
15.3%	15.3%	20.7%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

INDOUS₹78.36

Indo Us Biotech Limited

· FMCG & Retail

₹ CrorePeersKOHINOOR NATHBIOGEN AGRITECH SARVESHWAR SUKHJITS REGAAL BSHSL GULPOLYMcap ₹157 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.98	0.94	0.87
Interest Burden (Pretax/EBIT) ×	0.93	0.86	0.65
EBIT Margin %	17.18	14.59	7.94
Asset Turnover ×	1.06	0.96	0.96
Financial Leverage (Assets/Equity) ×	1.25	1.44	1.53
ROE (5-step product, year-end total equity) %	20.69	16.41	6.56
ROE (owners' profit / average owners' equity) %	20.72	15.34	15.34

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.